Empowering People to be Ambassadors of their Own Health Since 1997.


Weekly News

Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week.  Topics include all stories related to hepatitis C  as well as personal stories and events.



Week Ending February 8th 2016

Suing over drug prices is unlikely to succeed
“Everyone wants to pay less for prescription medicines, and Maura Healey believes she has a found a way to make it happen: by suing drug companies for violating state consumer protection laws.”

List of Approved Hepatitis C Medication
“When the drug Sovaldi (sofusbuvir) was first introduced into the market in September 2014, it marked not only a sea change in how we treated chronic hepatitis C (HCV) infection, it made obsolete earlier generation medications which demonstrated no where near the efficacy of this newer direct acting antiviral (DAA). Among them, Vertex Pharmaceutical’s Incivek (telapravir) and Merck’s Victrelis (boceprevir), both of which were voluntarily discontinued in October 2014 and December 2015, respectively.”

FDA approves Bristol Myers Squibb’s Daklinza’s for expanded use to treat patients with hepatitis C
“Bristol-Myers Squibb has announced that its hepatitis drug Daklinza (daclatasvir), an NS5A replication complex inhibitor has been approved by the US Food and Drug Administration for expanded use.”

Former VA Scientist Responds to Lawmaker’s Suspicions over Drug Sale
“A former Veterans Affairs Department scientist says he is willing and able to defend his reputation against lawmakers or others who suggest he invented a highly successful hepatitis C treatment using agency resources and later earned millions by selling it to a private company.”

Olysio/Sovaldi yield high SVR post-liver transplant
“In a retrospective study, a combination treatment regimen of Olysio and Sovaldi led to high sustained virologic response rates among patients with hepatitis C virus infection post-liver transplant and with advanced liver disease.”

Hep C Drug ‘Price War’ Looming
“Health experts are predicting a “price war” is looming over expensive hepatitis C drugs taken by many older Americans to treat the virus. Merck announced a list price of $54,000 for a 12-week course of Zepatier — a price significantly lower than two existing drugs.”

Congress outraged over hepatitis C treatment VA can’t afford
“Congress is looking into why veterans are being denied a cute for a deadly form of hepatitis.”

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)